New drug shows promise in shrinking hard-to-treat colorectal tumors before surgery
NCT ID NCT07352280
First seen Feb 01, 2026 · Last updated May 12, 2026 · Updated 9 times
Summary
This study looks at how well the drug tislelizumab works when given before surgery for people with a specific genetic type of stage II-III colorectal cancer (dMMR/MSI-H). About 30 participants will receive three cycles of the drug, then have surgery to remove the tumor. Researchers will track how many patients have no cancer left after treatment and monitor any side effects for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER (DMMR/MSI-H CRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Undefined, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.